SAN JOSE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader in innovative laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 3, 2026.
Third Quarter 2026 Financial Highlights
- Generated total revenue of $10.2 million, compared to $12.5 million in the prior year period
- Cyclo G6® product family revenue was $3.2 million, compared to $3.5 million in the prior year period
- Sold approximately 11,900 Cyclo G6 probes compared to 14,900 in the prior year period
- Sold 28 Cyclo G6 Glaucoma Laser Systems compared to 30 in the prior year period
- Retina product revenue was $5.1 million compared to $6.7 million in the prior year period
- Gross margin increased to 42.4%, compared to 32.1% in the prior year period and 34.2% in the second quarter of 2026
- Completed headquarter relocation to San Jose, expected to deliver approximately $600,000 in annualized savings
“On the top line, revenue came in below our expectations this quarter, driven by weaker than anticipated customer demand in Europe and Asia coupled with order delays late in the quarter as distributors worked through probe inventory and ongoing regulatory challenges. At the same time, we continue to experience the benefits from the cost savings programs initiated when I was named CEO, including the recent relocation of our headquarters,” said Patrick Mercer, President and CEO of Iridex.
“Considering the lower revenue and our investment in inventory to manage the manufacturing facility transition, cash utilization during the quarter was only $1 million and should decrease significantly in the fourth quarter with stronger sales and reversal of the inventory stocking process,” Mercer continued. “We are now deep into a strategic review of our product lines, and as part of that work we are reprioritizing our resources toward our most profitable opportunities. With this focus, we expect to enter 2027 with better margins, a lower cost base, and a business model better aligned toward cash flow generation.”
Third Quarter 2026 Financial Results
Total revenue for the three months ended October 3, 2026 was $10.2 million, representing a decline of 19% compared to the third quarter of 2025. The decrease was primarily driven by lower international retina sales and lower international probe orders, partially offset by growth in the U.S. glaucoma business. Total retina product revenue was $5.1 million compared to $6.7 million in the prior year period. The decrease was driven by international markets and external headwinds. Total product revenue from the Cyclo G6 product family was $3.2 million, compared to $3.5 million in the prior year period. International revenue declined as distributors elected to work through inventory purchased earlier in the year, partially offset by higher U.S. probe average selling prices and higher system revenue. Other revenue was $1.9 million compared to $2.2 million in the prior year period, mainly reflecting lower service revenue and the absence of royalty revenue in the current period.
Gross margin in the third quarter of 2026 was 42.4%, compared to 32.1%, in the prior year period. The improvement reflects a one-time write off recorded during the third quarter of 2025 of approximately $0.8 million to cost of goods sold and more favorable geographic mix and sustained pricing discipline. Excluding this impact, pro forma gross margin was 38.7%, representing a solid 370 basis point improvement. The Company expects the transition of its major products to third-party contract manufacturers to be the next significant driver of margin expansion through 2027.
Operating expenses were $5.5 million in the third quarter of 2026, essentially flat compared to $5.4 million in the third quarter of 2025.
Net loss was $1.4 million, or $0.08 per share, for the third quarter of 2026, compared to a net loss of $1.6 million, or $0.09 per share, in the same period of the prior year.
Non-GAAP adjusted EBITDA loss for the third quarter of 2026 was $0.6 million, compared to a non-GAAP adjusted EBITDA loss of $0.1 million for the third quarter of 2025.
Cash and cash equivalents as of October 3, 2026 were $3.7 million, a decrease of $1.0 million compared to July 4, 2026. Cash utilization is expected to decrease significantly with stronger sales and consumption of the safety stock inventory.
2026 Financial Outlook
Based on third quarter trends, which the Company expects to continue through the fourth quarter, the Company is reducing its annual revenue guidance for the full year 2026 to between $46 million and $48 million, from the prior range of $51 million to $53 million. This guidance continues to exclude revenue from the Middle East.
The Company continues to expect fiscal year 2026 adjusted operating expenses, which exclude depreciation and amortization and stock-based compensation, to be in the range of $19 million to $19.5 million.
Webcast and Conference Call Information
Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com or by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 7118799.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries.
For additional information, visit www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning commercial trends, market adoption and expansion, expectations regarding profitability, demand for and utilization of the Company’s products, financial results and forecasts and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the “Risk Factors” section of Iridex’s most recent Annual Report on Form 10-K, as well as in Iridex’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Iridex’s GAAP results, we consider Adjusted EBITDA. This non-GAAP result should not be considered as an alternative to net income, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present this non-GAAP result because management considers it to be an important supplemental measure of Iridex’s performance and refers to such measures when analyzing Iridex’s strategy and operations. In calculating the above non-GAAP result: Adjusted EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Adjusted EBITDA exclude from their GAAP equivalents items listed below:
- Share-based compensation expense. We excluded from our non-GAAP results the expense related to equity-based compensation plans as it represents expenses that do not require cash settlement from Iridex.
- Severance-related expenses. We excluded from our non-GAAP results the expenses related to restructuring events, partially offset by reversals of previously recognized severance expenses in subsequent periods. These expenses are unrelated to our ongoing operations, vary in size and frequency and are subject to significant fluctuations from period to period due to varying levels of restructuring activity. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
- Reconvention of shareholders’ meeting expenses. We excluded from our non-GAAP results the expenses related to the costs of reconvening our latest annual shareholders meeting. These expenses are unrelated to our ongoing operations and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
- Legal settlement expenses. We excluded from our non-GAAP results the expenses related to the non-recurring settlement of a legal case regarding the use of tracking software on the Company’s website. We believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
- Loss on write-down of inventory. We excluded from our non-GAAP results the expenses related to the write down of inventory related to the transfer of production of several products to 3rd party contract manufacturers. In these types of transactions, not all applicable inventories are acquired by the contract manufacturers and thus, such inventory becomes excess and obsolete. These expenses are unrelated to our ongoing operations, and we believe that excluding these expenses provides a more meaningful comparison of the financial results to our historical operations and to the financial results of peer companies.
Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.
A detailed reconciliation between Iridex’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Iridex’s other reports filed with or furnished to the SEC.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
| IRIDEX Corporation Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| October 3, 2026 | September 27, 2025 | October 3, 2026 | September 27, 2025 | |||||||||||||
| Total revenues | $ | 10,156 | $ | 12,484 | $ | 34,521 | $ | 37,951 | ||||||||
| Cost of revenues | 5,854 | 8,471 | 21,182 | 24,201 | ||||||||||||
| Gross profit | 4,302 | 4,013 | 13,339 | 13,750 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,014 | 972 | 2,855 | 2,719 | ||||||||||||
| Sales and marketing | 2,408 | 2,657 | 7,492 | 7,645 | ||||||||||||
| General and administrative | 2,043 | 1,795 | 5,508 | 5,942 | ||||||||||||
| Total operating expenses | 5,465 | 5,424 | 15,855 | 16,306 | ||||||||||||
| Loss from operations | (1,163 | ) | (1,411 | ) | (2,516 | ) | (2,556 | ) | ||||||||
| Other expense, net | (160 | ) | (158 | ) | (469 | ) | (1,660 | ) | ||||||||
| Loss from operations before provision for income taxes | (1,323 | ) | (1,569 | ) | (2,985 | ) | (4,216 | ) | ||||||||
| Provision for income taxes | 78 | 4 | 206 | 37 | ||||||||||||
| Net loss | $ | (1,401 | ) | $ | (1,573 | ) | $ | (3,191 | ) | $ | (4,253 | ) | ||||
| Net loss per share: | ||||||||||||||||
| Basic | $ | (0.08 | ) | $ | (0.09 | ) | $ | (0.18 | ) | $ | (0.25 | ) | ||||
| Diluted | $ | (0.08 | ) | $ | (0.09 | ) | $ | (0.18 | ) | $ | (0.25 | ) | ||||
| Weighted average shares used in computing net loss per common share: | ||||||||||||||||
| Basic | 17,593 | 17,009 | 17,441 | 16,843 | ||||||||||||
| Diluted | 17,593 | 17,009 | 17,441 | 16,843 | ||||||||||||
| IRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands) | ||||||||
| October 3, 2026 | January 3, 2026 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,673 | $ | 6,028 | ||||
| Accounts receivable, net | 4,775 | 9,545 | ||||||
| Inventories | 11,760 | 7,877 | ||||||
| Prepaid expenses and other current assets | 2,611 | 1,802 | ||||||
| Total current assets | 22,819 | 25,252 | ||||||
| Property and equipment, net | 210 | 58 | ||||||
| Intangible assets, net | 745 | 984 | ||||||
| Goodwill | 965 | 965 | ||||||
| Operating lease right-of-use assets, net | 3,615 | 768 | ||||||
| Other long-term assets | 918 | 1,124 | ||||||
| Total assets | $ | 29,272 | $ | 29,151 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 7,077 | $ | 5,502 | ||||
| Accrued compensation | 1,443 | 2,340 | ||||||
| Accrued expenses | 579 | 608 | ||||||
| Other current liabilities | 1,627 | 1,899 | ||||||
| Deferred revenue, current | 2,215 | 2,160 | ||||||
| Operating lease liabilities, current | 48 | 699 | ||||||
| Total current liabilities | 12,989 | 13,208 | ||||||
| Long-term liabilities: | ||||||||
| Deferred revenue | 5,702 | 6,801 | ||||||
| Operating lease liabilities | 3,561 | 98 | ||||||
| Convertible note payable | 3,825 | 3,735 | ||||||
| Other long-term liabilities | 568 | 387 | ||||||
| Total liabilities | 26,645 | 24,229 | ||||||
| Stockholders’ equity: | ||||||||
| Series B convertible preferred stock | 6,000 | 6,000 | ||||||
| Common stock | 178 | 174 | ||||||
| Additional paid-in capital | 92,100 | 91,208 | ||||||
| Accumulated other comprehensive loss | (14 | ) | (14 | ) | ||||
| Accumulated deficit | (95,637 | ) | (92,446 | ) | ||||
| Total stockholders’ equity | 2,627 | 4,922 | ||||||
| Total liabilities and stockholders’ equity | $ | 29,272 | $ | 29,151 | ||||
| IRIDEX Corporation Reconciliation of GAAP Net Loss to Adjusted EBITDA (In thousands) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| October 3, 2026 | September 27, 2025 | October 3, 2026 | September 27, 2025 | |||||||||||||
| Reconciliation of GAAP net loss to Adjusted EBITDA(a) | ||||||||||||||||
| GAAP net loss | $ | (1,401 | ) | $ | (1,573 | ) | $ | (3,191 | ) | $ | (4,253 | ) | ||||
| Interest income | (4 | ) | (10 | ) | (16 | ) | (31 | ) | ||||||||
| Other expense | 164 | 167 | 485 | 1,691 | ||||||||||||
| Provision for income taxes | 78 | 4 | 206 | 37 | ||||||||||||
| Nasdaq listing compliance | – | – | – | 152 | ||||||||||||
| Reconvention of shareholders’ meeting expenses | 67 | – | 129 | – | ||||||||||||
| Legal settlement expenses | – | – | 40 | – | ||||||||||||
| Depreciation and amortization | 260 | 366 | 994 | 1,125 | ||||||||||||
| Inventory write-down | – | 823 | – | 823 | ||||||||||||
| Stock-based compensation | 182 | 92 | 605 | 562 | ||||||||||||
| Severance related expense (for head count reduction) | 74 | – | 74 | 199 | ||||||||||||
| Adjusted EBITDA | $ | (580 | ) | $ | (131 | ) | $ | (674 | ) | $ | 305 | |||||
(a)Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as certain non-GAAP adjustments. | ||||||||||||||||